News

Several neurotech vendors and research teams pursuing advances in neuroprosthetics have reported significant developments in recent weeks. The steady progress offers hope to individuals with severe paralysis and other disabilities. Synchron, makers of a novel endovascular BCI, announced in May that they received an IDE from the FDA for the first-ever permanently implanted BCI in a human clinical trial.

Neurotech Reports, the publisher of this newsletter, announced that the third annual Neurotech Commercialization Workshop will take place on July 28, 2022. The one-day event, which was held on-line only in 2020 and 2021, will take place in New York City in 2022, in conjunction with the Neuroergonomics/NYC Neuromodulation conference, although there will be an option for on-line participation. The wo…

About 1500 neuromodulation professionals from all over the world assembled in Barcelona, Spain earlier this month for the 15th World Congress of the International Neuromodulation Society. The scientific program was preceded by an “Innovations in Neuromodulation” session dealing with commercialization issues. The full-day session, chaired from UI Chicago and Marc Russo from the Hunter Pain Clinic in…

Since the early days of the neurotechnology industry, a major challenge confronting vendors and researchers has been overcoming obstacles presented . Though much progress has been made, there is still a bias among many clinicians, regulators, payers, and patient advocacy groups who see drugs as the only viable therapy, and regard neurotech devices as a last resort, if at all. As NBR senior consulti…

The market for treating psychiatric disorders with neuromodulation therapy continues to progress as vendors report progress and investigators share new research findings. We reported last month on the formation of Inner Cosmos, which is developing a subcutaneous stimulation system for treating depression [NBR Apr22 p1]. Earlier this month, Neuronetics, the first neuromodulation firm to gain FDA cle…

Neurotech Reports, the publisher of this newsletter, announced that the third annual Neurotech Commercialization Workshop will take place on July 28, 2022. The one-day event, which was held on-line only in 2020 and 2021, will take place in New York City in 2022, in conjunction with the Neuroergonimcs/NYC Neuromodulation conference, although there will be an option for on-line participation. The wor…

About 85 professionals from the bioelectronic medicine industry participated in the 2021 Bioelectronic Medicine Forum, held online earlier this month. The fourth annual event will return to New York City in 2022. Keynote speaker at this year’s event was Murthy Simhambhatla, CEO of SetPoint Medical. He started ’s definition of bioelectronic medicine: “Stimulating nerves and tapping into the body’s i…

Readers of this publication have been exposed to a number of new and promising forms of neuromodulation that exploit novel anatomical targets or unique stimulation paradigms. As we report on page 1 of this issue, several new neuromodulation approaches for treating pain have emerged recently, including subwave neuromodulation, chemogenetic neuromodulation, and HD-SCS. While previous generations of new SCS paradigms have demonstrated clinical, if not financial success, these newest approaches have yet to be proven.

Venture capital professionals helping to build the bioelectronic medicine industry shared their insights on the investments climate at the 2022 Bioelectronic Medicine Forum held in New York City earlier this month. A panel discussion with three venture capital professionals active in the space brought out some valuable insights for startups established firms alike. The session was moderated Jennifer French.

In recent years, neural engineering researchers have developed novel methods of neuromodulation that exploit optical or optogenetic forms of stimulation, while other have pursued ultrasound approaches. A team at Boston University is now exploring optoacoustic technology as a new neuromodulation modality in an effort to combine the best attributes of both technologies. The optoacoustic process involves pulses of light that are converted into acoustic waves at ultrasonic frequencies.